Mark A Kroenke,Marta Starcevic Manning,Christina L Zuch de Zafra,Xinwen Zhang,Kevin D Cook,Michael Archer,Martijn P Lolkema,Jin Wang,Sarah Hoofring,Gurleen Saini,Famke Aeffner,Elizabeth Ahern,Elena Garralda Cabanas,Ramaswamy Govindan,Mun Hui,Shalini Gupta,Daniel T Mytych

Abstract:AMG 256 is a bi-specific, heteroimmunoglobulin molecule with an anti-PD-1 antibody domain and a single IL-21 mutein domain on the C-terminus. Nonclinical studies in cynomolgus monkeys revealed that AMG 256 administration led to the development of immunogenicity-mediated responses and indicated that the IL-21 mutein domain of AMG 256 could enhance the anti-drug antibody response directed toward the monoclonal antibody domain. Anti-AMG 256 IgE were also observed in cynomolgus monkeys. A first-in-human (FIH) study in patients with advanced solid tumors was designed with these risks in mind. AMG 256 elicited ADA in 28 of 33 subjects (84.8%). However, ADA responses were only robust and exposure-impacting at the 2 lowest doses. At mid to high doses, ADA responses remained low magnitude and all subjects maintained exposure, despite most subjects developing ADA. Limited drug-specific IgE were also observed during the FIH study. ADA responses were not associated with any type of adverse event. The AMG 256 program represents a unique case where nonclinical studies informed on the risk of immunogenicity in humans, due to the IL-21-driven nature of the response.

Corrigendum: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein

Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein

Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Corrigendum: Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence

Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Author Correction to ‘mevalonate Improves Anti-Pd-1/pd-l1 Efficacy by Stabilizing CD274 Mrna’ [acta Pharmaceutica Sinica B 13 (2023) 2585–2600]

Corrigendum: Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

Corrigendum: Cytosolic protein translation regulates cell asymmetry and function in early TCR activation of human CD8+ T lymphocytes

Corrigendum: Human IL-17 and TNF-α additively or synergistically regulate the expression of proinflammatory genes, coagulation-related genes, and tight junction genes in porcine aortic endothelial cells

Corrigendum: A matter of life or death: Productively infected and bystander CD4 T Cells in early HIV infection

Corrigendum: LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells

Corrigendum: Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients

Corrigendum: CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations